Coronary heart disease secondary prevention weight management
|
Coronary heart disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coronary heart disease secondary prevention weight management On the Web |
|
American Roentgen Ray Society Images of Coronary heart disease secondary prevention weight management |
|
FDA on Coronary heart disease secondary prevention weight management |
|
CDC on Coronary heart disease secondary prevention weight management |
|
Coronary heart disease secondary prevention weight management in the news |
|
Blogs on Coronary heart disease secondary prevention weight management |
|
Risk calculators and risk factors for Coronary heart disease secondary prevention weight management |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
If a woman's waist has a circumference greater than 35 inches and if a man's waist is greater than 40 inches, lifestyle changes and possible metabolic syndrome treatments should be initiated. The initial goal of weight loss therapy should be to reduce body weight by approximately 5-10 percent from the patient's baseline weight.
2011 AHA/ACCF Guidelines for Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease (DO NOT EDIT) [1]
Weight Management (DO NOT EDIT) [1]
| “ | Goal: Body mass index of 18.5 to 24.9 kg/m2; Waist circumference of <35 inches (<89 cm) in women and <40 inches (<102 cm) in men. | ” |
| Class I |
| "1. Body mass index and/or waist circumference should be assessed at every visit, and the clinician should consistently encourage weight maintenance/reduction through an appropriate balance of lifestyle physical activity, structured exercise, caloric intake, and formal behavioral programs when indicated to maintain/achieve a body mass index between 18.5 and 24.9 kg/m2. [2][3][4][5][6][7][8][9][10] (Level of Evidence: B)" |
| "2. If waist circumference (measured horizontally at the iliac crest) is ≥35 inches (≥89 cm) in women and ≥40 inches (≥102 cm) in men, therapeutic lifestyle interventions should be intensified and focused on weight management. [6][7][8][9][10] (Level of Evidence: B)" |
| "3.The initial goal of weight loss therapy should be to reduce body weight by approximately 5% to 10% from baseline. With success, further weight loss can be attempted if indicated. (Level of Evidence: C)" |
Sources
- 2011 AHA/ACCF Guidelines for Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Aterosclerotic Vascular Disease (DO NOT EDIT) [1]
References
- ↑ 1.0 1.1 1.2 Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA; et al. (2011). "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation". Circulation. 124 (22): 2458–73. doi:10.1161/CIR.0b013e318235eb4d. PMID 22052934.
- ↑ "Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health". Obes. Res. 6 Suppl 2: 51S–209S. 1998. PMID 9813653. Unknown parameter
|month=ignored (help) - ↑ Klein S, Burke LE, Bray GA; et al. (2004). "Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation". Circulation. 110 (18): 2952–67. doi:10.1161/01.CIR.0000145546.97738.1E. PMID 15509809. Unknown parameter
|month=ignored (help) - ↑ Grundy SM, Cleeman JI, Daniels SR; et al. (2005). "Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary". Crit Pathw Cardiol. 4 (4): 198–203. PMID 18340209. Unknown parameter
|month=ignored (help) - ↑ Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW (1999). "Body-mass index and mortality in a prospective cohort of U.S. adults". N. Engl. J. Med. 341 (15): 1097–105. doi:10.1056/NEJM199910073411501. PMID 10511607. Unknown parameter
|month=ignored (help) - ↑ 6.0 6.1 Jensen MK, Chiuve SE, Rimm EB; et al. (2008). "Obesity, behavioral lifestyle factors, and risk of acute coronary events". Circulation. 117 (24): 3062–9. doi:10.1161/CIRCULATIONAHA.107.759951. PMID 18541738. Unknown parameter
|month=ignored (help) - ↑ 7.0 7.1 Arnlöv J, Ingelsson E, Sundström J, Lind L (2010). "Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men". Circulation. 121 (2): 230–6. doi:10.1161/CIRCULATIONAHA.109.887521. PMID 20038741. Unknown parameter
|month=ignored (help) - ↑ 8.0 8.1 Lavie CJ, Milani RV, Ventura HO (2009). "Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss". J. Am. Coll. Cardiol. 53 (21): 1925–32. doi:10.1016/j.jacc.2008.12.068. PMID 19460605. Unknown parameter
|month=ignored (help) - ↑ 9.0 9.1 Gruberg L, Weissman NJ, Waksman R; et al. (2002). "The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?". J. Am. Coll. Cardiol. 39 (4): 578–84. PMID 11849854. Unknown parameter
|month=ignored (help) - ↑ 10.0 10.1 Jacobs EJ, Newton CC, Wang Y; et al. (2010). "Waist circumference and all-cause mortality in a large US cohort". Arch. Intern. Med. 170 (15): 1293–301. doi:10.1001/archinternmed.2010.201. PMID 20696950. Unknown parameter
|month=ignored (help)